Home>Topics>Stocks>Amicus Therapeutics

Amicus Therapeutics FOLD

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Edelman's Perceptive Advisors Buying Amicus Therapeutics Ahead Of Phase III Data Release


      Wed, 23 Jul 2014

      position." Perceptive's most recent buy is Amicus Therapeutics (NASDAQ: FOLD ) . The fund bought 8,339,444 shares on May ..... million additional shares were added on the day that Amicus announced trial updates and analysis Complete

    2. Amicus adds to yesterday's spike


      Tue, 1 Jul 2014

      Shares of Amicus Therapeutics ( FOLD +22.8% ) continue upward on a 7x surge in volume in early trading. Yesterday, prices peaked at $4.06 before easing a bit

    3. BUZZ- Amicus Therapeutics : On track to report trial data


      Mon, 30 Jun 2014

      ** Says on track to report data from a late-stage trial of its genetic disorder drug in the third quarter of this year

    4. Top-line data from migalastat clinical trial expected in Q3


      Mon, 30 Jun 2014

      Amicus Therapeutics ( FOLD ) says that top-line data and statistical analysis from the clinical trail ( Study 012 ) evaluating its oral small molecule pharmacological

    5. Amicus Therapeutics - Long Opportunity With Asymmetric Upside Potential And Near-Term Catalyst


      Fri, 27 Jun 2014

      Neuroscientist Investor : Name: Amicus Therapeutics ( FOLD ) Current share price: $2 ..... Summary of investment thesis: Amicus Therapeutics is a rare disease drug developer ..... partnership rights. However, FOLD has since updated clinical

    6. Amicus Therapeutics Still A "Show Me" Story


      Thu, 12 Jun 2014

      historical norms. On the flip side, and in a case like Amicus Therapeutics ( FOLD ), once investors have largely written off a company ..... interest and confidence. To be very clear, I believe Amicus still has a difficult road ahead of it. The data

    7. Amicus shares fall after Fabry drug fails late-stage study


      Thu, 20 Dec 2012

      (Reuters) - Amicus Therapeutics Inc lost nearly half of its market value after the company said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage...

    8. Amicus's shares tank after Fabry disease drug fails trial


      Wed, 19 Dec 2012

      (Reuters) - Amicus Therapeutics said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage study, sending its shares down 50 percent in extended...

    9. Dropping Coverage of Amicus


      Tue, 29 Jun 2010

      We are no longer providing equity research on Amicus Therapeutics FOLD . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    10. New Morningstar Analyst Report - Amicus Therapeutics , Inc.

      Stock Reports

      Wed, 16 Jun 2010

      Shire's collaboration with Amicus also bodes poorly for Amigal ..... only worsen the problem. Amicus is more dependent than ever ..... future drug development. Amicus aims to use its innovative ..... partner to market them abroad. Amicus Therapeutics aims to stand on the shoulders

    « Prev12Next »
    Content Partners